iclaprim
Small moleculeexperimental
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
5
Phase 3
4
Phase 4
0
Earliest trial started Jun 1, 2005 (NCT00299520)
Timeline
Indications
Mechanism of action
- Dihydrofolate reductase type 1INHIBITOR
dhfrI inhibitor
- Bacterial dihydrofolate reductaseINHIBITOR
Bacterial dihydrofolate reductase inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
COc1cc(Cc2cnc(N)nc2N)c2c(c1OC)OC(C1CC1)C=C2- Mol. weight
- 354.41 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL134561 ↗
- ChEMBLCHEMBL2105645 ↗
Also known as
- ar 100
- ar-100
- ar-100
- ar-100
- iclaprim
- iclaprim
- iclaprim
- iclaprim
- iclaprim
- iclaprim
- iclaprim
- iclaprim mesilate
- iclaprim mesylate
- ro-482622
- ro-482622
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02600611 | Phase 3 | Nov 1, 2015 | Motif BioSciences |
| NCT02607618 | Phase 3 | Nov 1, 2015 | Motif BioSciences |
| NCT00543608 | Phase 2 | Nov 1, 2007 | Arpida AG, Sharp HealthCare |
| NCT00303550 | Phase 3 | Mar 1, 2006 | Arpida AG |
| NCT00299520 | Phase 3 | Jun 1, 2005 | Arpida AG |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Arpida AG | For profit | 3 | 3 | 2 | 2005 |
| Motif BioSciences | For profit | 2 | 2 | 1 | 2015 |
| Sharp HealthCare | Academic/Hospital | 1 | 0 | 1 | 2007 |
3 organizations
Page 1 / 1